摘要
目的探讨帕利哌酮对首发精神分裂症患者不同时间非酶抗氧化物浓度的影响。方法 102例首发精神分裂症患者随机分为A组和B组各51例。A组给予利培酮治疗,B组给予帕利哌酮治疗。另选取51例健康体检人群为C组。比较A组、B组治疗前及治疗后4、8、12周时PANSS总分的变化情况,治疗总有效率,不良反应发生率及3组患者治疗前及治疗1、4、8、12周时白蛋白(ALB)、总胆红素(TBIL)、尿酸(UA)水平的变化。结果治疗4、8、12周后,A、B组PANSS总分均显著低于治疗前(P<0.05),且呈显著下降的趋势。A组总有效率为72.55%,略低于B组的80.40%。A组总不良反应发生率为33.3%,略高于B组的31.4%。治疗后,A、B组TBIL水平呈显著下降趋势(P<0.05),而UA水平呈显著上升趋势(P<0.05),2组组内比较无显著差异(P>.0.05),但2组TBIL水平均显著低于C组(P<0.05),UA水平均显著高于C组(P<0.05)。结论帕利哌酮能有效控制首发精神分裂症患者的症状,疗效与利培酮相当,但安全性更好,值得临床推广应用。
Objective To investigate effect of paliperidone on serum levels of non-enzymatic antioxidant in different time in patients with first-episode schizophrenic. Methods A total of 102 first-episode schizophrenic patients were randomly divided into group A and group B, with 51 cases per group. Group A and group B were treated with risperidone and paliperidone, respectively. Anoth- er 51 the healthy with physical examination were selected as group C. The changes of total PANSS score, incidence of adverse reactions and curative efficacy between group A and group B before and at 4, 8 and 12 weeks after treatment were compared. Besides, the changes of albumin (ALB), total bilirubin (TBIL), and uric acid (UA) levels of patients before treatment and at 1, 4, 8 and 12 weeks after treatment among 3 groups were also compared. Results At 4, 8 and 12 weeks after treatment, the total score of PANSS in groups A and B was significantly lower than the treatment before (P 〈0.05), and showed a significant decline. The total response rate of group A was 72.55% , slightly lower than that 80.40% in the group B. The total adverse reaction rate of group A was 33. 3% , which was slightly higher than 31.4% in group B. After treatment, TBIL levels in groups A and B was decreased significantly ( P 〈 0.05 ) , while the level of UA was significantly increased ( P 〈 0.05 ) , but there was no significant difference ( P 〉. 0.05 ). However, the levels of TBIL and UA were significantly lower and higher, respectively, in the two groups than that of group C (P 〈 0.05 ). Conclusion Paliperidone can effectively control the symptoms of patients with first-episode schizophrenic, and almost equals the efficacy of risperidone with safer use. So it is worth clinical application.
出处
《实用临床医药杂志》
CAS
2017年第24期34-37,共4页
Journal of Clinical Medicine in Practice
关键词
帕利哌酮
利培酮
首发精神分裂症
尿酸
白蛋白
总胆红素
paliperidone
fisperidone
first-episode schizophrenia
uric acid
albumin
total bilirubin